Sift Biosciences raised $3.7M in Pre-Seed funding from FreeFlow Zone and Lifespan Vision Ventures to build an AI-powered peptide immunotherapy platform. The company is targeting immunologically cold tumors by activating memory T cells through metagenomics and immune profiling. This represents early-stage development of AI-driven cancer immunotherapy, potentially expanding treatment options for previously difficult-to-treat tumor types.